Young adult patients (n = 68/143, 48%) were significantly less likely to receive initial approval compared with pediatric patients (n = 139/141; 99%) (P < .001). Given the decades of survivorship of YA patients, PBT is an important tool to reduce late toxicities and secondary malignancies. Insurance denials and subsequent appeal requests result in significant delays for YA patients.